Sun down on latest Indian US FDA import alert

By Dan Stanton

- Last updated on GMT

Related tags Import alert Sun pharma Pharmaceutical drug Food and drug administration Pharmacology Fda

Sun down on latest Indian US FDA import alert
Sun Pharma’s antibiotic facility import alert is the latest blow to the Indian drug industry but is unlikely to impact revenues or cause US shortages, the firm says.

The facility in Karkhadi, Gujarat produces cephalosporins, a class of β-lactam antibiotics, but in a filing with the Bombay Stock Exchange this morning Sun Pharmaceutical Industries announced the unit had been placed under an import alert by the US Food and Drug Administration (FDA).

The alert​ was issued following an inspection when the US agency identified some non-compliance of current Good Manufacturing Practice (cGMP) regulations, and thus drugs made from the facility may be detained without physical examination “until such time as FDA is satisfied that the appearance of a violation has been removed, either by reinspection or submission of appropriate documentation to the responsible FDA Center.”

Sun Pharma spokesperson Mira Desai told in-Pharmatechnologist.com the alert “has a negligible impact on company-wide revenues,”​ and would be unlikely to cause any shortages in the US.

Furthermore, she confirmed the firm has already initiated several corrective steps to address the observations made by the FDA but was unable to provide more details.

Shares in the firm fell by over 5% following the announcement.

Import Alert & India

The news sees Sun Pharma join a growing list of high profile Indian drugmakers who have had products headed for the US banned due to GMP violations.

All four of Ranbaxy’s facilities in India are subject to the alert – the API plant in Toansa​ becoming the latest to fall under the ban in January - whilst two of Wockhardt facilities​ fell under the import ban last year.

The FDA has spoken at length about ensuring quality from Indian suppliers, and Commissioner Margaret Hamburg visited the country last month in part to address this issue. A Statement of Intent was signed pledging cooperation in ensuring compliance between the US and Indian authorities, and the FDA has also said it would up the number of inspectors in the country​.

This specific Import Alert (66-40) cites 33 facilities in India where product imports are banned from. However, whilst much recent emphasis has been on India, 31 facilities in China are also affected by the ban. The next largest country is Germany, with eight plants banned from exporting their drugs to the US.

An antibiotic producing facility run by Sun Pharma has been hit with an import alert from the US FDA in the latest blow for Indian drug exporters.

The facility in Karkhadi, Gujarat is dedicated to producing cephalosporins, a class of β-lactam antibiotics, but in a filing with the Bombay Stock Exchange this morning Sun Pharmaceutical Industries announced the unit had been placed under an import alert by the US Food and Drug Administration (FDA).

The alert​ was issued following an inspection of the plant when the agency identified some non-compliance of current Good Manufacturing Practice (cGMP) regulations, and thus drugs made from the facility may be detained without physical examination “until such time as FDA is satisfied that the appearance of a violation has been removed, either by reinspection or submission of appropriate documentation to the responsible FDA Center.”

Sun Pharma spokesperson Mira Desai told in-Pharmatechnologist.com the alert “has a negligible impact on company-wide revenues,”​ and would be unlikely to cause any shortages in the US.

Furthermore, she confirmed the firm has already initiated several corrective steps to address the observations made by the FDA but was unable to provide more details.

Shares in the firm fell by over 5% following the announcement.

Import Alert & India

The news sees Sun Pharma join a growing list of high profile Indian drugmakers who have had products headed for the US banned due to GMP violations.

All four of Ranbaxy’s facilities in India are subject to the alert – the API plant in Toansa​ becoming the latest to fall under the ban in January - whilst two of Wockhardt facilities​ fell under the import ban last year.

The FDA has spoken at length about ensuring quality from Indian suppliers, and Commissioner Margaret Hamburg visited the country last month in part to address this issue. A Statement of Intent was signed pledging cooperation in ensuring compliance between the US and Indian authorities, and the FDA has also said it would up the number of inspectors in the country​.

This specific Import Alert (66-40) cites 33 facilities in India where product imports are banned from. However, whilst much recent emphasis has been on India, 31 facilities in China are also affected by the ban. The next largest country is Germany, with eight plants banned from exporting their drugs to the US.

Related news

Show more

Related products

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

A Guide Through the API Drug Development Pipeline

A Guide Through the API Drug Development Pipeline

Content provided by Lonza Small Molecules | 11-Jul-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Related suppliers

Follow us

Products

View more

Webinars